Engineered Dendritic Cell Vaccines for Multiple Myeloma

The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.

Trial Details

NCT ID
NCT06435910
Phase
PHASE1
Sponsor
Shenzhen Geno-Immune Medical Institute
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • DC vaccines
Locations (sample)
  • Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

  • Male and female subjects with multiple myeloma or plasmacytoma
  • Very good partial or complete remission (CR) after prior combination therapies.
  • Expected survival \> 12 weeks
  • Adequate venous access for blood withdrawal or apheresis, and no other contraindications for blood withdrawal

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →